I Corps: Development of Genome Edited Cancer Vaccines

I Corps：基因组编辑癌症疫苗的开发

• 批准号: 1924656
• 负责人: Kaiming Ye
• 金额: $ 5万
• 依托单位: SUNY at Binghamton
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2020-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1924656&HistoricalAwards=false
• 关键词: Corps; Development; Genome; Edited; Cancer

The broader impact/commercial potential of this I-Corps project is to bring a novel cancer immunotherapy vaccine to the market for treating solid and metastatic tumors. Solid tumors exhibit the highest rates of incidence and mortality in the United States for the past few decades. Many of the newest advancements in immunotherapy, including bi-specific antibodies and CAR-T cell therapy have shown minimal effect on solid tumors. The vaccine invented by this group fills the gap by providing a personalized immunotherapy vaccine that can stop or reduce the progression of the cancer and prevent its recurrence. It will save millions of lives by treating those incurable cancers with this newly developed vaccine. The plan is to investigate its customer segments, to discover its market, and to understand its regulatory approval processes. The initial customer discovery will be the focus of the NSF I-Corps Short Course, followed by a market discovery and a strategy to raise funds for bringing the vaccine to the market.This I-Corps project is to commercialize an immunotherapy vaccine that was developed based on a discovery made by this group, where genome edited tumor cells were found to elicit a strong immunogenicity against solid tumors, thereby functioning like a vaccine. The initial animal studies supported the feasibility of this approach. Building upon tremendous advances in cancer immunotherapy and genome editing, this vaccine synergistically combines CRISPR genome editing, vaccinations, and personalized medicine to fully activate a patient's immune system against cancer recurrence. This is the first engineered tumor vaccine that prevents cancer cells from evading the immune system. Unlike conventional cancer therapy, it does not have severe off-target side effects. While cancer vaccines have been explored extensively, their clinical development has seen a long lag phase due to hurdles in regulatory approvals and their adoption into existing therapy regimes. The vaccine developed by this group will overcome these hurdles.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛的影响/商业潜力是将新型的癌症免疫疗法疫苗带到治疗固体和转移性肿瘤的市场。在过去的几十年中，实体瘤在美国表现出最高的发病率和死亡率。免疫疗法中的许多最新进步，包括双特异性抗体和CAR-T细胞疗法，对实体瘤的影响很小。该组发明的疫苗通过提供个性化的免疫疗法疫苗来填补空白，该疫苗可以阻止或减少癌症的进展并防止其复发。通过使用这种新开发的疫苗来治疗那些无法治愈的癌症，它将挽救数百万的生命。该计划是调查其客户群，发现其市场并了解其监管批准流程。最初的客户发现将是NSF I-Corps短期课程的重点，其次是市场发现和筹集资金来将疫苗带入市场的策略。该I-Corps项目是将免疫疗法疫苗商业化，该疫苗是根据该组制造的一种发现的免疫疗法疫苗，该发现是由该基因组编辑的肿瘤细胞进行的，诸如基因组编辑的细胞具有强大的免疫原样，从而有效地否则，该疫苗是液化性的。最初的动物研究支持了这种方法的可行性。在癌症免疫疗法和基因组编辑方面的巨大进展的基础上，这种疫苗协同结合了CRISPR基因组编辑，疫苗接种和个性化医学，以完全激活患者的免疫系统，以防止癌症复发。这是第一次防止癌细胞逃避免疫系统的肿瘤疫苗。与常规的癌症治疗不同，它没有严重的脱靶副作用。尽管已经广泛探索了癌症疫苗，但由于监管部门批准的障碍及其对现有治疗方案的采用，他们的临床发育持续了很长的滞后阶段。该小组开发的疫苗将克服这些障碍。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子和更广泛影响的审查标准来评估值得支持的。